Alkermes plc (NASDAQ:ALKS - Free Report) - Stock analysts at Zacks Research increased their Q4 2025 earnings per share estimates for Alkermes in a research note issued on Thursday, June 19th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.53 per share for the quarter, up from their prior estimate of $0.51. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes' Q2 2026 earnings at $0.54 EPS, Q4 2026 earnings at $0.57 EPS and FY2026 earnings at $1.93 EPS.
ALKS has been the topic of a number of other research reports. Cantor Fitzgerald upgraded Alkermes to a "strong-buy" rating in a research report on Tuesday, May 13th. Needham & Company LLC initiated coverage on Alkermes in a report on Wednesday, May 28th. They issued a "buy" rating and a $45.00 price target for the company. Deutsche Bank Aktiengesellschaft boosted their price target on Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a report on Thursday, March 27th. Royal Bank Of Canada boosted their price target on Alkermes from $39.00 to $40.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Finally, Robert W. Baird boosted their price target on Alkermes from $38.00 to $41.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Three analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Alkermes has a consensus rating of "Moderate Buy" and an average target price of $40.00.
Get Our Latest Analysis on ALKS
Alkermes Stock Down 0.8%
Shares of NASDAQ ALKS opened at $29.09 on Monday. The business's 50 day moving average price is $29.81 and its 200 day moving average price is $31.02. The firm has a market cap of $4.80 billion, a P/E ratio of 13.92, a P/E/G ratio of 1.80 and a beta of 0.47. Alkermes has a 52 week low of $22.90 and a 52 week high of $36.45.
Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). The firm had revenue of $306.51 million during the quarter, compared to analysts' expectations of $307.53 million. Alkermes had a net margin of 23.30% and a return on equity of 27.52%. Alkermes's quarterly revenue was down 12.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 EPS.
Insider Transactions at Alkermes
In other news, SVP Christian Todd Nichols sold 3,334 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total transaction of $103,654.06. Following the completion of the transaction, the senior vice president now directly owns 86,208 shares of the company's stock, valued at $2,680,206.72. This represents a 3.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 4.40% of the company's stock.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Venturi Wealth Management LLC acquired a new position in Alkermes in the 4th quarter valued at $25,000. Twin Tree Management LP acquired a new position in Alkermes in the 1st quarter valued at $29,000. Brooklyn Investment Group raised its stake in Alkermes by 1,071.1% in the 1st quarter. Brooklyn Investment Group now owns 1,054 shares of the company's stock valued at $35,000 after purchasing an additional 964 shares during the last quarter. Quantbot Technologies LP raised its stake in Alkermes by 54.5% in the 1st quarter. Quantbot Technologies LP now owns 1,091 shares of the company's stock valued at $36,000 after purchasing an additional 385 shares during the last quarter. Finally, USA Financial Formulas acquired a new position in Alkermes in the 1st quarter valued at $49,000. 95.21% of the stock is owned by institutional investors and hedge funds.
About Alkermes
(
Get Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
